Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients

We completed a real-world analysis of 498 consecutive high-risk nonimmunocompromised and immunocompromised patients who received sotrovimab during the B.1.1.529 surge. Emergency department visits/hospitalizations and 30-day all-cause mortality between the 2 groups were similar. When administered ear...

Descripción completa

Detalles Bibliográficos
Autores principales: Birk, Navina K, Jain, Saniya, Massoud, Louis, Ramesh, Diya, Monday, Lea, Muma, Bruce, Williams, Jonathan, Alangaden, George, Ramesh, Mayur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214182/
https://www.ncbi.nlm.nih.gov/pubmed/35859992
http://dx.doi.org/10.1093/ofid/ofac282
_version_ 1784730953471492096
author Birk, Navina K
Jain, Saniya
Massoud, Louis
Ramesh, Diya
Monday, Lea
Muma, Bruce
Williams, Jonathan
Alangaden, George
Ramesh, Mayur
author_facet Birk, Navina K
Jain, Saniya
Massoud, Louis
Ramesh, Diya
Monday, Lea
Muma, Bruce
Williams, Jonathan
Alangaden, George
Ramesh, Mayur
author_sort Birk, Navina K
collection PubMed
description We completed a real-world analysis of 498 consecutive high-risk nonimmunocompromised and immunocompromised patients who received sotrovimab during the B.1.1.529 surge. Emergency department visits/hospitalizations and 30-day all-cause mortality between the 2 groups were similar. When administered early, sotrovimab is effective at preventing coronavirus disease 2019 progression in immunocompromised and nonimmunocompromised patients.
format Online
Article
Text
id pubmed-9214182
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-92141822022-06-22 Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients Birk, Navina K Jain, Saniya Massoud, Louis Ramesh, Diya Monday, Lea Muma, Bruce Williams, Jonathan Alangaden, George Ramesh, Mayur Open Forum Infect Dis Brief Report We completed a real-world analysis of 498 consecutive high-risk nonimmunocompromised and immunocompromised patients who received sotrovimab during the B.1.1.529 surge. Emergency department visits/hospitalizations and 30-day all-cause mortality between the 2 groups were similar. When administered early, sotrovimab is effective at preventing coronavirus disease 2019 progression in immunocompromised and nonimmunocompromised patients. Oxford University Press 2022-06-07 /pmc/articles/PMC9214182/ /pubmed/35859992 http://dx.doi.org/10.1093/ofid/ofac282 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Birk, Navina K
Jain, Saniya
Massoud, Louis
Ramesh, Diya
Monday, Lea
Muma, Bruce
Williams, Jonathan
Alangaden, George
Ramesh, Mayur
Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients
title Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients
title_full Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients
title_fullStr Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients
title_full_unstemmed Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients
title_short Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients
title_sort real-world experience of sotrovimab in high-risk, immunocompromised covid-19 patients
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214182/
https://www.ncbi.nlm.nih.gov/pubmed/35859992
http://dx.doi.org/10.1093/ofid/ofac282
work_keys_str_mv AT birknavinak realworldexperienceofsotrovimabinhighriskimmunocompromisedcovid19patients
AT jainsaniya realworldexperienceofsotrovimabinhighriskimmunocompromisedcovid19patients
AT massoudlouis realworldexperienceofsotrovimabinhighriskimmunocompromisedcovid19patients
AT rameshdiya realworldexperienceofsotrovimabinhighriskimmunocompromisedcovid19patients
AT mondaylea realworldexperienceofsotrovimabinhighriskimmunocompromisedcovid19patients
AT mumabruce realworldexperienceofsotrovimabinhighriskimmunocompromisedcovid19patients
AT williamsjonathan realworldexperienceofsotrovimabinhighriskimmunocompromisedcovid19patients
AT alangadengeorge realworldexperienceofsotrovimabinhighriskimmunocompromisedcovid19patients
AT rameshmayur realworldexperienceofsotrovimabinhighriskimmunocompromisedcovid19patients

Ejemplares similares